Release 5 Draft Ballot
Medication DefinitionThis page is part of the FHIR Specification (v4.6.0: R5 Draft Ballot). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions 
. Page versions: R5 R4B
| Biomedical Research and Regulation Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: Not linked to any defined compartments |
Raw Turtle (+ also see Turtle/RDF Format Specification)
Simple version of a product (more than basic), only using MedicinalProductDefinition, Ingredient and RegulatedAuthorization
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
<http://hl7.org/fhir/MedicinalProductDefinition/equilidem-with-ing-and-auth> a fhir:MedicinalProductDefinition;
fhir:nodeRole fhir:treeRoot;
fhir:Resource.id [ fhir:value "equilidem-with-ing-and-auth"];
fhir:DomainResource.text [
fhir:Narrative.status [ fhir:value "generated" ];
fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n <p>\n <b>\n Generated Narrative\n </b>\n </p>\n <p>\n <b>\n Id\n </b>\n : equilidem-with-ing-and-auth\n </p>\n <p>\n <b>\n Identifier\n </b>\n : Equilidem25\n </p>\n <p>\n <b>\n Combined Pharmaceutical Dose Form\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/dosefom tablet}\">\n tablet\n </span>\n </p>\n <p>\n <b>\n Indication\n </b>\n : Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\n </p>\n <p>\n <b>\n Legal Status Of Supply\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/legalstatusofsupply POM}\">\n Prescription only medicine\n </span>\n </p>\n <p>\n <b>\n classification\n </b>\n :\n <span title=\"Codes: {http://www.whocc.no/atc/example B01A}\">\n B01A\n </span>\n </p>\n <p>\n <b>\n Ingredients\n </b>\n :\n </p>\n <blockquote>\n <p>\n <b>\n Role\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/ingredientType active}\">\n active\n </span>\n </p>\n <blockquote>\n <p>\n <b>\n substance\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/substances 123456}\">\n Equilidonium Phosphate\n </span>\n </p>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Presentation\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n 22 ml/1 tablet\n </td>\n </tr>\n </table>\n </blockquote>\n </blockquote>\n <blockquote>\n <p>\n <b>\n Role\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/ingredientType excipient}\">\n excipient\n </span>\n </p>\n <blockquote>\n <p>\n <b>\n substance\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/substances 456789}\">\n Calcium Carbonate\n </span>\n </p>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Presentation\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n 3 ml/tablet\n </td>\n </tr>\n </table>\n </blockquote>\n </blockquote>\n <h3>\n Names\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n ProductName\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n Equilidem 2.5 mg film-coated tablets\n </td>\n </tr>\n </table>\n <h3>\n Cross References\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Product\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n Link to generic equivalent\n </td>\n </tr>\n </table>\n <h3>\n Manufacturing Business Operations\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Manufacturer\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n <span>\n EquiliDrugCo Processing Inc.\n </span>\n </td>\n </tr>\n </table>\n </div>"
];
fhir:DomainResource.contained [
a fhir:Ingredient;
fhir:index 0;
fhir:Resource.id [ fhir:value "EquilidoniumPhosphate" ];
fhir:Ingredient.role [
fhir:CodeableConcept.coding [
fhir:index 0;
fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/ingredientType" ];
fhir:Coding.code [ fhir:value "active" ]
]
];
fhir:Ingredient.substance [
fhir:Ingredient.substance.code [
fhir:CodeableReference.concept [
fhir:CodeableConcept.coding [
fhir:index 0;
fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/substances" ];
fhir:Coding.code [ fhir:value "123456" ];
fhir:Coding.display [ fhir:value "Equilidonium Phosphate" ]
]
]
];
fhir:Ingredient.substance.strength [
fhir:index 0;
fhir:Ingredient.substance.strength.presentationRatio [
fhir:Ratio.numerator [
fhir:Quantity.value [ fhir:value "22"^^xsd:decimal ];
fhir:Quantity.unit [ fhir:value "ml" ]
];
fhir:Ratio.denominator [
fhir:Quantity.value [ fhir:value "1"^^xsd:decimal ];
fhir:Quantity.unit [ fhir:value "tablet" ]
]
]
]
]
], [
a fhir:Ingredient;
fhir:index 1;
fhir:Resource.id [ fhir:value "CalciumCarbonate" ];
fhir:Ingredient.role [
fhir:CodeableConcept.coding [
fhir:index 0;
fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/ingredientType" ];
fhir:Coding.code [ fhir:value "excipient" ]
]
];
fhir:Ingredient.substance [
fhir:Ingredient.substance.code [
fhir:CodeableReference.concept [
fhir:CodeableConcept.coding [
fhir:index 0;
fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/substances" ];
fhir:Coding.code [ fhir:value "456789" ];
fhir:Coding.display [ fhir:value "Calcium Carbonate" ]
]
]
];
fhir:Ingredient.substance.strength [
fhir:index 0;
fhir:Ingredient.substance.strength.presentationRatio [
fhir:Ratio.numerator [
fhir:Quantity.value [ fhir:value "3"^^xsd:decimal ];
fhir:Quantity.unit [ fhir:value "ml" ]
];
fhir:Ratio.denominator [
fhir:Quantity.value [ fhir:value "1"^^xsd:decimal ];
fhir:Quantity.unit [ fhir:value "tablet" ]
]
]
]
]
];
fhir:MedicinalProductDefinition.identifier [
fhir:index 0;
fhir:Identifier.system [ fhir:value "http://example.org.uk/fhir/product" ];
fhir:Identifier.value [ fhir:value "Equilidem25" ]
];
fhir:MedicinalProductDefinition.combinedPharmaceuticalDoseForm [
fhir:CodeableConcept.coding [
fhir:index 0;
fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/dosefom" ];
fhir:Coding.code [ fhir:value "tablet" ]
]
];
fhir:MedicinalProductDefinition.indication [ fhir:value "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."];
fhir:MedicinalProductDefinition.legalStatusOfSupply [
fhir:CodeableConcept.coding [
fhir:index 0;
fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/legalstatusofsupply" ];
fhir:Coding.code [ fhir:value "POM" ];
fhir:Coding.display [ fhir:value "Prescription only medicine" ]
]
];
fhir:MedicinalProductDefinition.classification [
fhir:index 0;
fhir:CodeableConcept.coding [
fhir:index 0;
fhir:Coding.system [ fhir:value "http://www.whocc.no/atc/example" ];
fhir:Coding.code [ fhir:value "B01A" ]
]
];
fhir:MedicinalProductDefinition.ingredient [
fhir:index 0;
fhir:CodeableReference.reference [
fhir:Reference.reference [ fhir:value "#EquilidoniumPhosphate" ]
]
], [
fhir:index 1;
fhir:CodeableReference.reference [
fhir:Reference.reference [ fhir:value "#CalciumCarbonate" ]
]
];
fhir:MedicinalProductDefinition.name [
fhir:index 0;
fhir:MedicinalProductDefinition.name.productName [ fhir:value "Equilidem 2.5 mg film-coated tablets" ]
];
fhir:MedicinalProductDefinition.crossReference [
fhir:index 0;
fhir:MedicinalProductDefinition.crossReference.product [
fhir:CodeableReference.reference [
fhir:link <http://hl7.org/fhir/MedicinalProductDefinition/genericEquilidonium>;
fhir:Reference.reference [ fhir:value "MedicinalProductDefinition/genericEquilidonium" ]
]
]
];
fhir:MedicinalProductDefinition.operation [
fhir:index 0;
fhir:MedicinalProductDefinition.operation.organization [
fhir:index 0;
fhir:Reference.display [ fhir:value "EquiliDrugCo Processing Inc." ]
]
] .
<http://hl7.org/fhir/MedicinalProductDefinition/genericEquilidonium> a fhir:MedicinalProductDefinition .
# - ontology header ------------------------------------------------------------
<http://hl7.org/fhir/MedicinalProductDefinition/equilidem-with-ing-and-auth.ttl> a owl:Ontology;
owl:imports fhir:fhir.ttl;
owl:versionIRI <http://build.fhir.org/MedicinalProductDefinition/equilidem-with-ing-and-auth.ttl> .
# -------------------------------------------------------------------------------------
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
FHIR ®© HL7.org 2011+. FHIR R5 Draft Ballot hl7.fhir.core#4.6.0 generated on Thu, Apr 15, 2021 12:29+1000.
Links: Search |
Version History |
Table of Contents |
QA Page |
Compare to R4 |
|
Propose a change